Digital repository of Slovenian research organisations

Show document
A+ | A- | Help | SLO | ENG

Title:Naše izkušnje z zdravilom bevacizumab v primarnem zdravljenju epitelijskega raka jajčnikov
Authors:ID Škof, Erik (Author)
ID Mangaroski, Dushan (Author)
Files:.pdf PDF - Presentation file, download (173,87 KB)
MD5: CCEB34A438FAA2ACC1D4DE36538A2489
 
Language:Slovenian
Typology:1.01 - Original Scientific Article
Organization:Logo OI - Institute of Oncology
Abstract:Izhodišče: Zdravilo bevacizumab uporabljamo v sklopu primarnega sistemskega zdravljenja napredovalega epitelijskega raka jajčnikov v kombinaciji s paklitakselom in karboplatinom od leta 2013. Namen: Prikazati učinkovitost in varnost zdravljenja z bevacizumabom v redni klinični praksi v sklopu primarnega zdravljenja raka jajčnikov. Metode: V retrospektivno analizo smo vključili bolnice z epitelijskim rakom jajčnikov, ki so se zdravile z bevacizumabom na Onkološkem inštitutu Ljubljana v obdobju od 1. 1. 2013 do 31. 12. 2016. Cilja raziskave sta bila varnost in učinkovitost (preživetje brez ponovitve bolezni, celokupno preživetje) zdravljenja z bevacizumabom. Raziskavo je odobrila etična komisija na Onkološkem inštitutu Ljubljana. Rezultati: V opazovanem obdobju je bilo z bevacizumabom zdravljenih 111 bolnic z napredovalim epitelijskim rakom jajčnikov. Najpogostejši neželeni učinki so bili: bolečine (52 %), krvavitev (45 %), arterijska hipertenzija (44 %). Resne neželene učinke (stopnja 3/4) je imelo 12 % bolnic: venska tromboza/ embolija (3 %), proteinurija (3 %), arterijska hipertenzija (2 %), krvavitev (2 %), bolečine (1 %), fistula (1 %). Mediani čas sledenja je bil 59 mesecev. Mediano preživetje brez ponovitve bolezni je bilo 18 mesecev, mediano celokupno preživetje pa 41 mesecev. Zaključki: Zdravljenje z bevacizumabom v redni klinični praksi je varno in učinkovito ‒ v skladu z do zdaj znanimi rezultati prospektivnih raziskav GOG 218 in ICON 7.
Keywords:rak jajčnikov, epitelijski rak, bevacizumab, kemoterapija
Publication status:Published
Publication version:Version of Record
Year of publishing:2020
Number of pages:str. 20-24
Numbering:Letn. 24, št. 1
PID:20.500.12556/DiRROS-12404 New window
UDC:618.1
ISSN on article:1408-1741
DOI:10.25670/oi2020-0030n New window
COBISS.SI-ID:24701955 New window
Copyright:by Authors
Publication date in DiRROS:09.09.2020
Views:2544
Downloads:654
Metadata:XML DC-XML DC-RDF
:
ŠKOF, Erik and MANGAROSKI, Dushan, 2020, Naše izkušnje z zdravilom bevacizumab v primarnem zdravljenju epitelijskega raka jajčnikov. Onkologija [online]. 2020. Vol. 24, no. 1, p. 20–24. [Accessed 25 March 2025]. DOI 10.25670/oi2020-0030n. Retrieved from: https://dirros.openscience.si/IzpisGradiva.php?lang=eng&id=12404
Copy citation
  
Share:Bookmark and Share


Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:Onkologija
Shortened title:Onkologija
Publisher:Onkološki inštitut
ISSN:1408-1741
COBISS.SI-ID:65324032 New window

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:01.06.2020

Secondary language

Language:English
Title:Our experience with bevacizumab in the primary treatment of epithelial ovarian cancer
Abstract:Introduction: Bevacizumab has been used in advanced epithelial ovarian cancer patients as a part of standard primary systemic therapy together with paclitaxel and carboplatin combination chemotherapy since 2013. Aim of study: To evaluate the safety and efficacy of bevacizumab in treatment of patients with advanced epithelial ovarian cancer in daily clinical practice. Methods: Retrospective analysis of patients with advanced epithelial cancer treated with bevacizumab at the Institute of Oncology Ljubljana in the period from 1 Jan 2013 to 31 Dec 2016. The end points of the study were safety and efficacy (relapse-free survival, overall survival). The study was approved by our institutional ethics board. Results: In the observed period, a total of 111 patients with advanced epithelial ovarian cancer were treated with bevacizumab. The most common adverse events were: pain (52%), bleeding (45%), and arterial hypertension (44%). Serious adverse events (grade 3/4) were observed in 12% of patients: 3% venous thrombosis/ embolism, 3% proteinuria, 2% arterial hypertension, 2% bleeding, 1% pain, and 1% fistula. Median follow up was 59 months. Median progression-free survival was 18 months, while median overall survival was 41 months. Conclusions: Treatment with bevacizumab in daily clinical practice is safe and effective – in concordance with published data from prospective studies GOG 218 and ICON 7.


Archive

niGradiv

Back